Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 182

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 182
---
 11,413,759 |   |
| Cash                                                                                                                  
 and cash equivalents at end of year                                                                                   |     | $    |  1,105,291 |   |     | $    |  2,821,570 |   |
| Supplemental disclosures                                                                                              
 of cash flow information:                                                                                             |     |      |            |   |     |      |            |   |
| Income taxes paid in                                                                                                  
 cash                                                                                                                  |     | $    |     11,650 |   |     | $    |     20,993 |   |
| Interest paid                                                                                                         |     |      |     17,610 |   |     |      |     37,125 |   |
| Noncash investing activities:                                                                                         |     |      |            |   |     |      |            |   |
| Stock issuance in connection                                                                                          
 with the acquisition                                                                                                  |     | $    |          — |   |     | $    |  1,000,000 |   |
| Noncash financing activities:                                                                                         |     |      |            |   |     |      |            |   |
| Fair value of warrants                                                                                                
 issued to placement agents                                                                                            |     | $    |     74,281 |   |     |      |          — |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.</div>

| F-6 |

bioAffinity Technologies, Inc.

Notes to Consolidated Financial Statements

For the Years Ended December 31, 2024 and 2023

Note 1. BASIS OF PRESENTATION, ORGANIZATION AND NATURE OF OPERATIONS

Description of Business

bioAffinity Technologies, Inc., a Delaware corporation (the “Company,” or “bioAffinity Technologies”), addresses the need for noninvasive diagnosis of lung cancer at early stage and other diseases of the lung. bioAffinity Technologies’ proprietary platform uses flow cytometry and automated data analysis built by machine learning, a form of artificial intelligence, to preferentially target cancer cell populations and other cell populations indicative of a diseased state. The Company’s first diagnostic test, CyPath ®Lung, is a noninvasive test for early detection of lung cancer, the leading cause of cancer-related deaths. CyPath ®Lung is offered for sale to physicians by the Company’s subsidiary, Precision Pathology Laboratory Services, LLC (“PPLS”). The Company also conducted and intends to seek